Skip to main content
. 2009 Jun 27;30(18):2233–2240. doi: 10.1093/eurheartj/ehp253

Figure 6.

Figure 6

Patient-assessed dyspnoea response by baseline subgroup represented as treatment effect (>0.5 favours tolvaptan) and 95% confidence interval.